The Control Problem: Why Fear of Dilution Is Keeping Scientists From the Table

A computational biologist at a Danish university founded a spinout in 2018 around a platform for protein structure prediction — work that predated the public attention AlphaFold would later attract to the field, and that had independent commercial applications in drug discovery. At his first serious investor meeting, he was offered a seed round that valued the company at a pre-money figure his instinct told him was too low. He did not know how to say so. He did not know what number to counter with, or on what basis, or what the consequences of a lower valuation at seed would be for his ownership stake at Series A. He accepted the terms. Three years later, after two further dilutive rounds, he held less than eight percent of the company he had founded. He retained no board seat. A strategic acquirer purchased the company at a valuation that would, under different early terms, have returned him financial independence. Instead, it returned him a figure that barely covered the income he had forgone.

He is not unusual. He is, in most respects, representative — of a generation of researcher-founders who built genuinely valuable things and then negotiated for them without preparation, without data, and without anyone in the room whose job was to protect their interest. The fear of dilution and loss of control is one of the most cited anxieties among academic entrepreneurs. What receives far less attention is that this fear, when unaddressed, becomes a self-fulfilling prophecy — not because equity dilution is inevitable, but because the researcher who enters a negotiation unprepared almost always leaves it with less than they needed to.

The origins of the vulnerability are structural and long-established. Scientific training is, among other things, an extended education in a particular kind of negotiation — the negotiation of meaning, of evidence, of priority in the literature. It is not, in any institutional sense, an education in the negotiation of value. Doctoral programmes do not include cap table mechanics. Postdoctoral fellowships do not cover convertible note structures. The researcher who arrives at a first funding conversation has spent a decade learning to be precise about molecules, mechanisms, and statistical significance. They have typically spent no time learning what a liquidation preference is, why pro-rata rights matter, or how a down round restructures the ownership landscape they thought they had secured.

This knowledge gap began to matter structurally in the late 1990s and early 2000s, as university spinout activity accelerated following the wave of European Bayh-Dole equivalent legislation and as venture capital began actively courting deep-tech founders from academic backgrounds. The mismatch that resulted was acute and asymmetric: on one side of the table, investors and their counsel with decades of deal experience and detailed knowledge of every term's downstream implication; on the other, researchers encountering these instruments for the first time, frequently without independent legal advice, and in many cases so grateful for investment interest that challenging any term felt like risking the whole relationship.

The fear that researchers carry into funding conversations is not only financial. It is, more fundamentally, a fear about the fate of the work itself. A researcher who has spent a decade developing a technology has a relationship to it that no investor shares — an understanding of its potential, its limitations, and its correct development path that exists nowhere else. The prospect of ceding control to a board that might redirect that development for reasons of portfolio strategy, or pressure for premature commercialisation, or simply lack the technical depth to distinguish a productive pivot from a destructive one, is not irrational. It reflects a genuine and well-documented risk.

The psychological dimension compounds the structural one in ways that are rarely examined directly. Researchers who have spent their careers in an environment where competence is demonstrated through published work and peer recognition frequently experience a specific form of impostor anxiety in commercial negotiations — a sense that their authority in this room is contingent and provisional in a way that it never is in a seminar. The investor across the table has done this hundreds of times. The researcher is doing it for the first. That asymmetry of experience is real, and it manifests in specific behavioural patterns: accepting the first offer to avoid appearing difficult, failing to counter because counteroffering feels presumptuous, agreeing to terms without fully understanding them because admitting incomprehension feels professionally humiliating.

The longer-term consequences extend beyond individual financial outcomes. Researchers who feel they lost control of their work through an opaque funding process withdraw from commercialisation — not just once, but as a career posture. They return to the grant cycle not because it serves the science better, but because it is the only funding environment in which the terms are comprehensible and the power dynamics legible. The talent lost to deep-tech commercialisation through this mechanism is considerable and almost entirely unmeasured.

What changes the outcome is, at its core, preparation of a specific and practical kind. Not a general education in venture capital mechanics — though that helps — but targeted preparation for the specific negotiation the researcher is about to enter, grounded in the actual numbers that define the value of the technology they are bringing to the table.

A researcher who arrives at a funding conversation knowing the current market comparable for their sector, the typical valuation range for technologies at their stage of development, the standard deal structures for their technology category, and — critically — the minimum equity retention and governance provisions they need to maintain meaningful control of the development roadmap, is a different negotiating counterparty than one who arrives without this information. They can justify a counter. They can explain what they are protecting and why. They can distinguish between terms that are standard and terms that are unfavourable, and they can do so in language that does not read as naivety or aggression but as the reasonable position of someone who has done their homework.

This is what genuine preparation looks like in practice: market data that establishes the value of the technology in commercial terms, a clear understanding of what comparable deals have looked like, and the rehearsed ability to hold a negotiating position under the social pressure that funding conversations inevitably generate. It is not about turning researchers into hardened dealmakers. It is about ensuring that when a researcher sits across from an investor with a term sheet, they are not negotiating blind. They have the numbers. They know what the work is worth. And they have, for the first time, a basis for saying — calmly, clearly, and with complete professional authority — that the terms need to change.